CN109311825A - 新型2,4,6-三取代均三嗪化合物及其制备方法和应用 - Google Patents

新型2,4,6-三取代均三嗪化合物及其制备方法和应用 Download PDF

Info

Publication number
CN109311825A
CN109311825A CN201780028741.2A CN201780028741A CN109311825A CN 109311825 A CN109311825 A CN 109311825A CN 201780028741 A CN201780028741 A CN 201780028741A CN 109311825 A CN109311825 A CN 109311825A
Authority
CN
China
Prior art keywords
base
alkyl
phenyl
amino
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780028741.2A
Other languages
English (en)
Other versions
CN109311825B (zh
Inventor
姚其正
吴剑平
陈瑞环
张磊
姚世宁
莫廉
张青青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LUODA BIOSCIENCES Inc
Nanjing Shiqi Pharmaceutical Co ltd
Original Assignee
LUODA BIOSCIENCES Inc
Nanjing Shiqi Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LUODA BIOSCIENCES Inc, Nanjing Shiqi Pharmaceutical Co ltd filed Critical LUODA BIOSCIENCES Inc
Publication of CN109311825A publication Critical patent/CN109311825A/zh
Application granted granted Critical
Publication of CN109311825B publication Critical patent/CN109311825B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明提供了一种通式(I)所示的2,4,6‑三取代‑1,3,5‑三嗪化合物或者其药学上可接受的盐、前药或溶剂合物，其制备方法以及这些化合物在制备用于预防或者治疗与蛋白激酶和波形蛋白调节异常、细胞空泡化有关疾病，尤其是用于治疗或者预防癌症生长与转移、组织的纤维化和动脉粥样硬化的药物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201780028741.2A 2016-05-12 2017-05-11 2,4,6-三取代均三嗪化合物及其制备方法和应用 Active CN109311825B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016103258090 2016-05-12
CN201610325809 2016-05-12
PCT/CN2017/083914 WO2017193954A1 (zh) 2016-05-12 2017-05-11 新型2,4,6-三取代均三嗪化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN109311825A true CN109311825A (zh) 2019-02-05
CN109311825B CN109311825B (zh) 2022-03-22

Family

ID=60266897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780028741.2A Active CN109311825B (zh) 2016-05-12 2017-05-11 2,4,6-三取代均三嗪化合物及其制备方法和应用

Country Status (13)

Country Link
US (2) US10611736B2 (zh)
EP (1) EP3456712B1 (zh)
JP (1) JP6987125B2 (zh)
KR (1) KR102379959B1 (zh)
CN (1) CN109311825B (zh)
AU (1) AU2017262920B2 (zh)
BR (1) BR112018072869B1 (zh)
CA (1) CA3023854A1 (zh)
DK (1) DK3456712T3 (zh)
ES (1) ES2913982T3 (zh)
RU (1) RU2737085C2 (zh)
SG (1) SG11201809760TA (zh)
WO (1) WO2017193954A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2737085C2 (ru) 2016-05-12 2020-11-24 Наньцзин Шици Фармасьютикал Ко. Лтд. Новое соединение 2,4,6-тризамещенного s-триазина, способ его получения и его применение
CN109796407A (zh) * 2018-12-29 2019-05-24 鼎元(天津)生物医药科技有限公司 一种模块化制备化学小分子探针的方法及应用
CN116829543A (zh) * 2021-02-03 2023-09-29 滁州市洛达生物科技有限公司 治疗或预防波形蛋白介导的疾病的化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1578663A (zh) * 2001-09-14 2005-02-09 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
WO2009138758A2 (en) * 2008-05-14 2009-11-19 Biolipox Ab Bis-aryl compounds for use as medicaments
CA2764980A1 (en) * 2009-06-09 2010-12-16 California Capital Equity, Llc Styryl-triazine derivatives and their therapeutical applications
CN102250065A (zh) * 2011-05-20 2011-11-23 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
US20140322128A1 (en) * 2011-02-24 2014-10-30 The University Of Toledo Materials and Methods Useful to Induce Cell Death via Methuosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377636B2 (en) * 2007-04-13 2013-02-19 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to kinase inhibitors
JP2011520979A (ja) * 2008-05-23 2011-07-21 ワイス・エルエルシー ＰＩ３キナーゼおよびｍＴＯＲ阻害剤としてのトリアジン化合物
WO2010144522A1 (en) * 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
RU2737085C2 (ru) 2016-05-12 2020-11-24 Наньцзин Шици Фармасьютикал Ко. Лтд. Новое соединение 2,4,6-тризамещенного s-триазина, способ его получения и его применение

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1578663A (zh) * 2001-09-14 2005-02-09 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
WO2009138758A2 (en) * 2008-05-14 2009-11-19 Biolipox Ab Bis-aryl compounds for use as medicaments
CA2764980A1 (en) * 2009-06-09 2010-12-16 California Capital Equity, Llc Styryl-triazine derivatives and their therapeutical applications
CN102573482A (zh) * 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 苯乙烯基-三嗪衍生物及其治疗应用
US20120178758A1 (en) * 2009-06-09 2012-07-12 California Capital Equity, Llc Styryl-triazine derivatives and their therapeutical applications
US20140322128A1 (en) * 2011-02-24 2014-10-30 The University Of Toledo Materials and Methods Useful to Induce Cell Death via Methuosis
CN102250065A (zh) * 2011-05-20 2011-11-23 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F. SĄCZEWSKI，等: "Synthesis, structure and anticancer activity of novel alkenyl-1,3,5-triazine derivatives", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
SG11201809760TA (en) 2018-12-28
US10611736B2 (en) 2020-04-07
RU2737085C2 (ru) 2020-11-24
KR20190003765A (ko) 2019-01-09
US11390591B2 (en) 2022-07-19
DK3456712T3 (da) 2022-05-30
KR102379959B1 (ko) 2022-03-29
JP2019515049A (ja) 2019-06-06
EP3456712A4 (en) 2019-12-04
US20190144399A1 (en) 2019-05-16
RU2018141762A (ru) 2020-06-15
BR112018072869A2 (pt) 2019-04-30
AU2017262920B2 (en) 2021-05-20
RU2018141762A3 (zh) 2020-06-15
WO2017193954A1 (zh) 2017-11-16
EP3456712A1 (en) 2019-03-20
ES2913982T3 (es) 2022-06-07
CN109311825B (zh) 2022-03-22
BR112018072869B1 (pt) 2024-02-27
EP3456712B1 (en) 2022-04-20
AU2017262920A1 (en) 2018-11-29
CA3023854A1 (en) 2017-11-16
US20200190042A1 (en) 2020-06-18
JP6987125B2 (ja) 2021-12-22

Similar Documents

Publication Publication Date Title
AU781506B2 (en) Integrin expression inhibitors
TWI324154B (zh)
CN102977014B (zh) 新的喹啉类化合物及其用途
JP2015524448A (ja) アルキニルへテロ芳香環化合物及びその応用
TW200403060A (en) Inhibitors of tyrosine kinases
PT1725528E (pt) Sulfonilpirróis como inibidores de hdac
US11390591B2 (en) 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
Tilekar et al. Permuted 2, 4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells
CN105705493A (zh) 喹唑啉衍生物、其制备方法、药物组合物和应用
WO2021017996A1 (zh) 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
WO2022199289A1 (zh) 新型雄激素受体降解剂、制备方法和医药用途
CN107151233B (zh) 含腙的嘧啶类衍生物及其用途
CN111247137A (zh) 一种嘧啶类化合物、其制备方法及其医药用途
CN109988120A (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
CN114539129B (zh) 烯丙胺类双功能化合物及其用途
CN112812056B (zh) N-吡啶-4-基苯甲酰胺Cdc37抑制剂及其衍生物和用途
CN108047204A (zh) 2,4-二芳氨基嘧啶衍生物及其制备方法和应用
CN107056771A (zh) Bromodomain蛋白二价抑制剂及其制备方法和应用
WO2023241738A2 (zh) 1,4-苯二氮䓬类化合物及其在制备抗肿瘤药物中的用途
CN105669521B (zh) 抗肿瘤化合物及其制备方法和应用
WO2023186881A1 (en) P38 map kinase inhibitors for use in the treatment of colorectal cancer
Jose et al. Fragment-based and structure-guided discovery of perforin inhibitors
CN115232030A (zh) 芳基脲类化合物及其制法和药物用途
CN114957219A (zh) 一种靶向降解Gli1蛋白的降解剂及其制备方法和应用
CN111187262A (zh) 咪唑并[1,2-a]吡啶衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001487

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant